ACKR3 and extramammary Paget disease: Therefore, both CXCR4 and CXCR7 can be used as biomarkers for prediction of the aggressiveness of EMPD, and therapies targeting CXCR4 and CXCR7 may be helpful to prevent EMPD progression [64].